Tag:

Nycomed

Latest Headlines

Latest Headlines

NPS Pharma goes global with $80M deal to buy back Takeda's Gattex rights

NPS Pharmaceuticals has locked up the global rights to Gattex. The biotech bought back the ex-U.S. rights to its newly approved orphan drug (teduglutide) alongside another drug program close to a U.S. filing for rare cases of hypoparathyroidism, handing over $50 million in stock--a 7% equity stake in the company--with another $30 million on the table if the company hits a key sales milestone.

Ariad lands Jonathan E. Dickinson as general manager, Europe

Welcome to this week's roundup of hirings and firings throughout the industry. Please send the good word (or the bad) from your shop to Jennifer Levin ( email | Twitter ) and we will feature it...

Ex-Nycomed chief to take chairman's seat at Lundbeck

Björklund had been CEO at the Swiss drugmaker Nycomed, until it sold out to Takeda Pharmaceuticals in 2011.

Private equity's pharma hopes exemplified by Nycomed

If you've ever wondered why private equity investors are such big buyers and sellers in the pharma world, look no further than Nycomed . As Forbes explains, Nordic Capital, a small Swedish firm...

EC antitrust squad drops AZ-Nycomed probe

AstraZeneca ( $AZN ) and Nycomed are in the clear, at least as far as European regulators are concerned. The European Commission's antitrust squad has dropped an investigation of the two companies...

Wyeth puts $960M squeeze on Sun for Protonix launch

Sun Pharmaceuticals ' at-risk launch of generic Protonix may prove to have been risky indeed. Pfizer's ( $PFE ) Wyeth unit slapped the Indian drugmaker with a $960 million damages claim, alleging Sun's

Astellas scores highest in Japanese M&A bout

Japan’s biggest pharma players have been roaming the world in recent years in a restless search for new acquisitions. They've been looking for deals to put an extra oomph into their earnings.

Takeda abandons Euro rights to Durect's controlled-release pain drug

For the second time this year, Durect ($DRRX) faces a setback over its controlled-release anti-pain drug Posidur. The Cupertino, CA-based company disclosed that its European development and marketing

Takeda to ax 2,800 workers, consolidate R&D in global restructuring

Four months after closing its $14 billion Nycomed buyout, Japan's Takeda says it will take an ax to its R&D operations as it sheds 2,800 employees. Most of the layoffs will occur in Europe, with

Takeda's plate full with Nycomed integration

Takeda Pharmaceutical says its $13.7 billion acquisition of Nycomed is enough to digest for now. Despite the strong yen, which has been fueling Japanese companies' buyouts abroad, Takeda President